Viridian Therapeutics (NASDAQ: VRDN) revenue
Viridian Therapeutics reported revenue of $70.8m for fiscal 2025, 23,359.9% more than in fiscal 2024 ($0.3m). Since fiscal 2016 its revenue has grown by 1,937.6%, an average growth of 39.8% a year.
Fiscal 2025 is the highest of the 10 fiscal years on record for Viridian Therapeutics. The biggest drop was in fiscal 2023, −82.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $70.8m | +23,359.9% | −$363.4m | −512.9% |
| 2024 | $0.3m | −3.8% | −$299.0m | −99,018.2% |
| 2023 | $0.3m | −82.3% | −$254.5m | −81,035.0% |
| 2022 | $1.8m | −40.2% | −$134.3m | −7,579.2% |
| 2021 | $3.0m | +182.2% | −$79.7m | −2,690.8% |
| 2020 | $1.1m | −76.5% | −$110.4m | −10,512.4% |
| 2019 | $4.5m | −46.8% | −$42.0m | −941.0% |
| 2018 | $8.4m | +109.5% | −$33.1m | −394.5% |
| 2017 | $4.0m | +15.1% | −$26.5m | −662.8% |
| 2016 | $3.5m | — | −$17.0m | −488.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Viridian Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Viridian Therapeutics ranks 311th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Viridian Therapeutics, 23,359.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 309th | Electromed | $73.8m | 15.3% |
| 310th | Assembly Biosciences | $72.3m | 153.5% |
| 311th | Viridian Therapeutics | $70.8m | 23,359.9% |
| 312th | Codexis | $70.4m | 18.6% |
| 313th | Black Diamond Therapeutics | $70.0m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Viridian Therapeutics
- How much revenue did Viridian Therapeutics make in fiscal 2025?
- Viridian Therapeutics reported revenue of $70.8m for fiscal 2025, compared with $0.3m in fiscal 2024.
- How much has the revenue of Viridian Therapeutics grown?
- Between fiscal 2016 and fiscal 2025 it went from $3.5m to $70.8m: 1,937.6% more, an average growth of 39.8% a year.
- What was the best year for revenue at Viridian Therapeutics?
- Of its last 10 fiscal years, fiscal 2025, with $70.8m.
- Where does Viridian Therapeutics rank in its sector by revenue?
- It ranks 311th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Viridian Therapeutics come from?
- From the annual report (Form 10-K) that Viridian Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Viridian Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Viridian Therapeutics: the Viridian Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.